secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celcuity Inc. (CELC)
CIK:        0001603454
Form:       8-K
Filed at:   2025-09-10T23:59:59+00:00
Accession:  0001641172-25-027025
Event type: debt
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celcuity upsizes senior secured facility to $500M, receives $30M immediate funding
--------------------------------------------------------------------------------

- Total facility increased to $500M ($350M committed + $150M discretionary); $30M funded, total outstanding $130M.
- Adds $100M upon FDA approval of gedatolisib in 2L wild-type advanced breast cancer; $120M upon commercial milestones.
- Maturity extended to Nov 1, 2029; interest-only period extended by 14 months, with possible 7-month FDA-approval extension.
- Issued warrants for 50,537 shares to lenders; cashless exercise through tenth anniversary of Term D funding.
- Funds will support NDA rolling submission via FDA's RTOR program, commercial launch prep, and strategic initiatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603454/000164117225027025/0001641172-25-027025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603454/000164117225027025/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-027025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer